Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 2099

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 2
Chunk 2099
---
 FLOW

    For the  period from  February 14,  2024 through December 31, 2024  
    For the  period from  January 1, 2024 through  February 13, 2024  
    For the year ended  December 31, 2023 

    (Successor)  
    (Predecessor)  
    (Predecessor) 
  
    Cash flows from operating activities: 

    Net loss 
    $(7,732,212) 
    $(572,211) 
    $(7,289,577)
  
    Adjustments to reconcile net loss to net cash used in operating activities: 

    Gain from settlement of liabilities with vendors 
     (3,339,223) 
     -  
     - 
  
    Depreciation expense 
     400,825  
     37,356  
     460,722 
  
    Stock-based compensation 
     924,668  
     4,431  
     96,896 
  
    Amortization of right-to-use operating lease asset 
     609,339  
     115,859  
     656,476 
  
    Amortization of debt discount 
     -  
     (1,875) 
     - 
  
    Non-cash interest expense 
     -  
     -  
     35,655 
  
    Gain on revaluation of earnout and derivative liabilities 
     (4,880,000) 
     (320,117) 
     (290,264)
  
    Change in assets and liabilities: 

    Prepaid expenses and other current assets 
     (87,088) 
     142,687  
     (112,321)
  
    Accounts payable 
     130,032  
     128,429  
     1,280,560 
  
    Accrued liabilities 
     2,342,593  
     (50,370) 
     44,239 
  
    Operating lease liability 
     (647,503) 
     (121,589) 
     (672,373)
  
    Net cash used in operating activities 
     (12,278,569) 
     (637,400) 
     (5,789,987)